Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: A trial of the Chicago, PMH, and California Phase II consortia

Abstract

There was no strong suggestion that this combination was superior to single agent bevacizumab, and the rate of gastrointestinal perforation was of concern. The study was therefore stopped. Identification of risk factors for gastrointestinal perforation will be of importance for the use of bevacizumab in the treatment of ovarian cancer.

Targeted molecular therapies for ovarian cancer: An update and future perspectives (Review)

“…Patients treated with erlotinib and bevacizumab are at high risk for severe and fatal gastrointestinal perforation. The study was therefore terminated due to the disappointing results of targeted therapy and severe toxicity in this setting (41).…”

Gene Amplification in Ovarian Carcinomas: Lessons from Selected Amplified Gene Families

“…Single agent TKI did not show any substantial clinical benefit (0-9% for gefitinib (Posadas et al 2007, Schilder et al 2005, 0% for CI-1033 an irreversible EGFR inhibitor (Campos et al 2005)). TKIs combined with cytotoxic chemotherapy, anti-angiogenic therapy, or hormonal therapy have also shown limited clinical efficacy and in some cases excessive toxicity (Campos et al 2010, Chambers et al 2010, Nimeiri et al 2008, Vasey et al 2008. The reason behind the relative failure of EGFR targeted therapies is not understood, but may be related to constitutive activation of downstream pathways, overexpression of ligands, or activation of alternative signaling pathways (reviewed in (Bianco et al 2007, Siwak et al 2010).…”

Role of vascular endothelial growth factor inhibitors in the treatment of gynecologic malignancies

“…However, thus far preliminary data suggest lack of additional benefit for anti-EGFR-1 drugs. 70 Another trial is evaluating the combination of bevacizumab with Sorafenib, attempting to exploit simultaneous blockade of VEGF and its receptors, as well as other pathways potentially involved in ovarian cancer progression.…”